SCHEMBL4865087

SCHEMBL4865087

CCSc1nc(NC(CC)COC)c2ccccc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.42
KDM4E B2RXH2 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
POLB P06746 2/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 5/20 0.41
KCNH2 Q12809 2/20 0.40
SOS1 Q07889 1/20 0.40
TLR8 Q9NR97 2/20 0.40
TSHR P16473 1/20 0.40
TLR7 Q9NYK1 1/20 0.40
TP53 P04637 2/20 0.39
MAPK1 P28482 1/20 0.38
GBA1 P04062 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
HIF1A Q16665 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4868605 0.81 MEN1 (0.56) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4866091 0.80 APP (0.57) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4865136 0.80 ACP1 (0.60) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL4867969 0.79 MAPT (0.59) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL5108077 0.77 MAPT (0.59) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL11247112 0.76 LDHA (0.58) MAPTMEN1KMT2APOLBALDH1A1
SCHEMBL4866137 0.73 ACP1 (0.60) MAPTKDM4EPOLBALDH1A1LMNA
SCHEMBL4863789 0.71 GBA1 (0.65) MAPTKDM4EMEN1KMT2APOLB
SCHEMBL4863793 0.71 APP (0.62) MAPTKDM4EMEN1KMT2APOLB
SCHEMBL4867045 0.70 ACP1 (0.63) MAPTKDM4EPOLBALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US claimed
JP-2008526734-A 2008-07-24 JP claimed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP claimed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO claimed
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2008-08-28 US disclosed
EP-1844023-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2007-10-17 EP disclosed
WO-2006071095-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY SK CHEMICALS CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207614-A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DIABETES AND OBESITY GPR119, GCKR, GLP1R MAPT 4050/4885KDM4E 1731/4885MEN1 3837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.